Nymox Pharmaceutical (NYMX) Reports Positive Update On Nerve Sparing And Sexual Function Preservation In Men Treated With NX-1207
6/17/2014 9:06:23 AM
HASBROUCK HEIGHTS, N.J., June 17, 2014 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) is pleased to report new data supporting the positive sexual functional preservation profile of NX-1207, the Company's lead compound in Phase 3 development for the treatment of prostate enlargement (BPH or benign prostatic hyperplasia) and Phase 2 development for localized prostate cancer. A detailed study of prostate tissues from men who had received intraprostatic injections of NX-1207 2.5 mg or 15 mg found that nervous tissues in the prostate after treatment were left intact and showed no damage. These new results showing that NX-1207 is nerve-sparing add to the considerable body of evidence that treatment with NX-1207 does not lead to the debilitating sexual side effects often associated with existing prostate treatments.
Help employers find you! Check out all the jobs and post your resume.
comments powered by